Oct 8 (Reuters) - Werewolf Therapeutics Inc HOWL.O:
WEREWOLF THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FROM THE U.S. FDA FOR WTX-124, AN INVESTIGATIONAL THERAPY FOR THE TREATMENT OF CANCER
WEREWOLF THERAPEUTICS INC: ANTICIPATE SHARING PRELIMINARY DATA FROM ONGOING WTX-124 PHASE 1/1B CLINICAL TRIAL IN Q4